Clinical trials: CNS Germ Cell Tumor
Cancer, Acute Lymphoblastic Leukemia
A Pilot RCT of the PRISM Intervention for AYAs With Cancer
Study Title: A Pilot Randomized Controlled Trial of the Promoting Resilience in Stress Management (PRISM) Intervention for Adolescents and Young Adults with Cancer Study Population and Sample Size: Two cohorts of Adolescent and…
- Conditions
- Cancer, Acute Lymphoblastic Leukemia, Lymphoma, Sarcoma
- Trial name
- NCT02340884
- Testing
- Promoting Resilience In Stress Management (PRISM)
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Seattle Children's Hospital
Anaplastic Astrocytoma, Anaplastic Ependymoma
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Meningioma, Anaplastic Oligodendroglioma
- Trial name
- NCT01082926
- Testing
- therapeutic allogeneic lymphocytes, aldesleukin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- City of Hope Medical Center
Leptomeningeal Disease, Glioblastoma
ctDNA-Guided Intraventricular Therapy for CNS Malignancies
This prospective, single-center study will evaluate whether cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) testing using the Belay Summit assay can improve the clinical management of patients with malignant gliomas or…
- Conditions
- Leptomeningeal Disease, Glioblastoma, Brain Metastases, Non-Small Cell Lung Cancer
- Trial name
- GUIDE-CNS (NCT07689721)
- Testing
- CSF ctDNA-Guided Clinical Management
- Volunteers
- 77 people
- Sponsor
- Alireza Mansouri
Malignant Neoplasms of Eye, Brain and Other Parts of Central Nervous System
S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00017147
- Testing
- carmustine, radiation therapy, O6-Benzylguanine
- Where
- 163 sites in United States
- Volunteers
- 183 people
- Sponsor
- SWOG Cancer Research Network
Brain and Central Nervous System Tumors
Combination Chemotherapy and Radiation Therapy in Treating Patients With Germ Cell Tumors in the Brain
RATIONALE: Drugs used in chemotherapy, such as carboplatin, etoposide, ifosfamide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00293358
- Testing
- carboplatin, cisplatin, etoposide phosphate
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 500 people
- Sponsor
- Children's Cancer and Leukaemia Group
Brain and Central Nervous System Tumors
Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT01019434
- Testing
- temozolomide, temsirolimus
- Where
- 13 sites in Belgium, France and 6 more
- Volunteers
- 111 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
Expanded Access to ANG1005 for Individual Patients
This is an expanded access study with ANG1005 treatment for two individual patients from Protocol ANG1005-CLN-03 with WHO Grade III Anaplastic Astrocytoma and WHO Grade III Anaplastic Oligodendroglioma and one individual patient…
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Breast Cancer With Recurrent Brain Metastases, Leptomeningeal Carcinomatosis
- Trial name
- NCT02755987
- Testing
- ANG1005
- Where
- 2 sites in United States
- Sponsor
- Angiochem Inc
Advanced Malignant Glioma, Anaplastic Astrocytomas
AMG 595 First-in-Human in Recurrent Gliomas
This is an open-label, sequential dose exploration study of single agent AMG 595 administered in subjects with recurrent glioblastoma multiforme (GBM) and/or anaplastic astrocytomas (AA).
- Conditions
- Advanced Malignant Glioma, Anaplastic Astrocytomas, Glioblastoma Multiforme
- Trial name
- NCT01475006
- Testing
- AMG 595
- Where
- 4 sites in United States, Australia
- Volunteers
- 32 people
- Sponsor
- Amgen
Kidney Cancer, Leukemia
Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy
RATIONALE: Voriconazole may be effective in preventing systemic fungal infections following chemotherapy. PURPOSE: Phase II trial to study the effectiveness of voriconazole in preventing systemic fungal infections in children who…
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00066599
- Testing
- voriconazole
- Where
- 7 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Medulloblastoma, Childhood, Childhood Cancer
Dual Task Training On Children With Ataxia After Medulloblastoma Resection
Medulloblastoma is a rapidly-growing tumor of the cerebellum, this area controls balance, posture and sophisticated motor functions like finer hand movements, speech, and swallowing.
- Trial name
- NCT04860934
- Testing
- Dual Task Training Program Group, Control Group
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Children's Cancer Hospital Egypt 57357
Central Nervous System Tumor, Pediatric, Glioma
EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells that are lentivirally transduced to express an EGFR806 specific chimeric antigen receptor (CAR) and…
- Conditions
- Central Nervous System Tumor, Pediatric, Glioma, Ependymoma, Medulloblastoma
- Trial name
- NCT03638167
- Testing
- EGFR806-specific chimeric antigen receptor (CAR) T cell
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Seattle Children's Hospital
Brain and Central Nervous System Tumors
Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005951
- Testing
- irinotecan hydrochloride, temozolomide
- Where
- United States
- Sponsor
- Duke University
Brain Tumor, Brain Necrosis
Development of MRF for Characterization of Brain Tumors After Radiotherapy
The purpose of this study is to discover the potential convenience and ease of using a Magnetic Resonance Imaging (MRI) technique, named Magnetic Resonance Fingerprinting (or MRF), to achieve high-quality images within a short…
- Conditions
- Brain Tumor, Brain Necrosis, Brain Metastases, Glioma
- Trial name
- NCT06101069
- Testing
- MRF in conjunction with IVIM MRI without contrast
- Where
- 2 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Case Comprehensive Cancer Center
Melanoma, Non-small Cell Lung Carcinoma (NSCLC)
LITT and Pembrolizumab in Recurrent Brain Metastasis
This is an open-label, historically controlled pilot study investigating the immune effect of Laser Interstitial ThermotHerapy (LITT)+ pembrolizumab in adult patients with a primary cancer approved by the FDA for treatment with…
- Conditions
- Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC), Small-cell Lung Cancer
- Trial name
- TORCH (NCT04187872)
- Testing
- LITT + Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Florida
RECURRENT GLIOBLASTOMA, Brain Tumor
Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)
This protocol is designed to generate and provide preliminary data to determine the safety and activity of combination therapy using tumor treating fields (TTFields; Optune(NovoTTF-100A); Novocure, Haifa, Israel), a novel…
- Trial name
- NCT01925573
- Testing
- Optune(NOVOTTF-100A)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Maryland, Baltimore
Recurrent Glioma, High-grade Meningioma
Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors
This is an open label phase I clinical trial with two arms, representing single and fractionated radiation therapy (Figure 4.1). Within each arm the radiation dose is pre-determined and not escalated.
- Conditions
- Recurrent Glioma, High-grade Meningioma, Brain Metastasis
- Trial name
- NCT01324635
- Testing
- Panobinostat, Stereotactic body radiation therapy, Quality-of-life assessment
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Basal Ganglia Germinoma, Diabetes Insipidus
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
This phase II trial studies how well lower dose radiotherapy after chemotherapy (Carboplatin \& Etoposide) works in treating children with central nervous system (CNS) germinomas.
- Conditions
- Basal Ganglia Germinoma, Diabetes Insipidus, Germinoma, Pineal Region Germinoma
- Trial name
- NCT06368817
- Testing
- 3-Dimensional Conformal Proton Radiation Therapy, 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection
- Where
- 115 sites in United States, Australia and 1 more
- Volunteers
- 240 people
- Sponsor
- Children's Oncology Group
Diffuse Intrinsic Pontine Glioma or Glioblastoma
Immune Modulatory DC Vaccine Against Brain Tumor
This study is designed to treat patients who have been diagnosed with brain cancer, including glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG).
- Trial name
- NCT03914768
- Testing
- Immunomodulatory DC vaccine to target DIPG and GBM
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Brain and Central Nervous System Tumors
Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00998010
- Testing
- bortezomib + temozolomide+ radiation therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Jonsson Comprehensive Cancer Center
NF2-related Schwannomatosis, NF2
Luvometinib in Combination With Serplulimab for NF2-Related Tumors
This is an investigator-initiated, exploratory, multicenter, open-label, single-arm clinical trial and a substudy of the Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2).
- Conditions
- NF2-related Schwannomatosis, NF2, Neurofibromatosis Type 2, Vestibular Schwannoma
- Trial name
- NCT07708285
- Testing
- Luvometinib, Serplulimab
- Where
- 5 sites in China
- Volunteers
- 30 people
- Sponsor
- Beijing Tiantan Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.